Of the $98 million in country grants approved by Global Fund Board from 2017-2019 allocations, Latin America and Caribbean receive $57 million
This is the second of two articles in this issue on the grants recently approved by the Global Fund Board. In this article, we report on the comments of the Grant Approvals Committee (GAC) on four countries in the Latin American and Caribbean region: Belize, El Salvador, Panama and Paraguay.
On 12 November 2018, through electronic voting, the Global Fund Board approved $98.0 million in funding for 14 country grants from 13 countries. Of the 14 grants, four were for TB; three TB/HIV; three HIV; three malaria; and one TB/RSSH.
Elimination 8 (E8) has set the formidable target of full malaria elimination in Botswana, Namibia, South Africa and Swaziland by 2020. Termed the “frontline four”, these countries are nearing elimination of the disease after achieving a 75% decline between 2000 and 2012.
Botswana’s country coordinating mechanism (CCM) is the first to conduct a performance self-assessment using a tool developed by Aidspan and Southern African AIDS Trust.
As one of six Southern African countries engaged in an Aidspan-led effort to improve engagement and performance at the CCM level, Botswana used the tool during a workshop in late 2013 to map where attention should be paid over 2014.
A High Level Panel led by former President Mogae of Botswana and former US Secretary of Health and Human Services Michael Leavitt has recommended in its report, released yesterday, that the Global Fund make some major changes in its structure and working methods.
The Global Fund Board has decided that any country whose economy is classified as upper-middle-income, and that had a high enough disease burden to be eligible to apply for Round 6 HIV/AIDS grants, will also be eligible to apply in Round 7. As a result, South Africa, Botswana and Equatorial Guinea will not be excluded from Round 7 eligibility as they would have been if this ruling had not been made.